Vieworks Showcases X-ray Imaging Excellence: RSNA 2023 Spotligh

Vieworks, a renowned digital x-ray imaging solutions provider, is set to unveil pioneering advancements at RSNA 2023 in Chicago (Booth 1723, November 26th-29th). Building on the success of prior RSNA exhibitions, Vieworks will present its comprehensive range of DR flat panel detectors (FPDs) catering to general radiography, dynamic applications, and mammography. The focal point remains on the latest VIVIX-S F series, accompanied by the revolutionary VIVIX-S 1751S—a long-format detector tailored for imaging larger body parts and long bones.

The spotlight on the FDA-approved VIVIX-S F series persists, showcasing its glass-free TFT design, lightweight construction, and extended battery life, enhancing the imaging experience for practitioners. In response to industry demands for imaging larger body parts in fixed static DR applications, Vieworks expands its portfolio with the introduction of VIVIX-S 4747V, the largest single FPD, alongside the VIVIX-S 1751S, first showcased at ECR in March.

In harmony with its commitment to “Clearer Vision. Safer Imaging,” Vieworks introduces three groundbreaking software technologies at RSNA 2023. “Deep Denoising,” a deep learning-based technology, ensures imaging at the lowest radiation dose without compromising clarity or anatomical detail. “Bone Suppression,” seamlessly integrated into VXvue software, facilitates precise and safe diagnosis by delivering clear suppressed images without additional radiation exposure. The third innovation, an “AEC-embedded solution,” optimizes radiation levels for unparalleled image quality, highlighting a focus on safety and efficiency.

Seungki Hong, Vice President of Vieworks, conveyed his enthusiasm about the company’s participation in RSNA 2023. He emphasized Vieworks’ steadfast commitment to innovation, underlining how the VIVIX-S 1751S and the latest software technologies exemplify their dedication to advancing medical imaging. Additionally, he underscored Vieworks’ mission to establish new standards in imaging quality and safety, ensuring that practitioners have access to state-of-the-art solutions for precise diagnostics and patient care.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”